(Q37939660)

25 August 2017

1 reference

title

The efficacy and safety of liraglutide (English)

1 reference

25 August 2017

1 reference

Kyeong-Hye Jeong

1

1 reference

25 August 2017

Bong Kyu Yoo

series ordinal

2

1 reference

25 August 2017

publication date

28 September 2011

1 reference

International Journal of Clinical Pharmacy

25 August 2017

published in

1 reference

25 August 2017

volume

33

1 reference

25 August 2017

issue

5

1 reference

25 August 2017

page(s)

740-749

1 reference

Liraglutide, a long-acting human glucagon-like peptide 1 analog, improves glucose homeostasis in marginal mass islet transplantation in mice.

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11096-011-9552-8

Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-011-9552-8

Molecular modeling of the three-dimensional structure of GLP-1R and its interactions with several agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-011-9552-8

Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on beta-cell function in normal living conditions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-011-9552-8

Stimulation of pancreatic beta-cell replication by incretins involves transcriptional induction of cyclin D1 via multiple signalling pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-011-9552-8

New treatments in type 2 diabetes: a focus on the incretin-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-011-9552-8

Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-011-9552-8

Pharmacokinetics and pharmacodynamics of liraglutide, a long-acting, potent glucagon-like peptide-1 analog

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-011-9552-8

Differentiating incretin therapies based on structure, activity, and metabolism: focus on liraglutide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-011-9552-8

Incorporating incretin-based therapies into clinical practice: differences between glucagon-like Peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-011-9552-8

Liraglutide: A once-daily human glucagon-like peptide-1 analogue for type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-011-9552-8

Glucagon-like peptide-1 analog and insulin combination therapy in the management of adults with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-011-9552-8

Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-011-9552-8

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-011-9552-8

Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-011-9552-8

Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-011-9552-8

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-011-9552-8

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-011-9552-8

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-011-9552-8

One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label tr

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-011-9552-8

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-011-9552-8

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-011-9552-8

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-011-9552-8

Cardiovascular complications in diabetes: targets and interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-011-9552-8

The global burden of diabetes and its complications: an emerging pandemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-011-9552-8

Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-011-9552-8

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-011-9552-8

Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes, 1999-2002: the National Health and Nutrition Examination Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-011-9552-8

Improvement in A1C levels and diabetes self-management activities following a nutrition and diabetes education program in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-011-9552-8

Pharmacokinetics, pharmacodynamics, tolerability, and safety of exenatide in Japanese patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-011-9552-8

Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-011-9552-8

Tolerability, pharmacokinetics and pharmacodynamics of the once-daily human GLP-1 analog liraglutide in Japanese healthy subjects: a randomized, double-blind, placebo-controlled dose-escalation study.

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21952951

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

A biomarker concept for assessment of insulin resistance, beta-cell function and chronic systemic inflammation in type 2 diabetes mellitus.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21952951

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Measuring progress toward achieving hemoglobin A1c goals in diabetes care: pass/fail or partial credit

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21952951

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S11096-011-9552-8

1 reference

25 August 2017

1 reference